|
|
|
|
|
Session Highlights from the 2021 Annual Meeting
|
|
|
|
| Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of Expanded Cohort 6 of the COSMIC-021 Study
|
| Neeraj Agarwal, MD
|
| Neeraj Agarwal presented results of the COSMIC-021 cohort 6, examining the role of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Dr. Agarwal highlighted that these data from Cohort 6 of COSMIC-021 demonstrate that cabozantinib + atezolizumab has clinically meaningful activity with a manageable safety profile in mCRPC, supporting a phase 3 study of cabozantinib + atezolizumab versus second NHT.
|
|
|
|
|
|
| Cabozantinib in Combination with Atezolizumab in Patients with mCRPC: Results of Expanded Cohort 6 of the COSMIC-021 Study: Invited Discussant
|
| Cora N. Sternberg, MD, FACP
|
| Following the presentation from Neeraj Agarwal of the results of expanded cohort 6 of the COSMIC-021 Study utilizing cabozantinib + atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC), Cora Sternberg provided an invited discussion to contextualize these results considering the question of immunotherapy and tyrosine kinase inhibitors in mCRPC.
|
|
|
|
|
|
| PRINCE: Interim Analysis of the Phase Ib Study of 177Lu-PSMA-617 in Combination with Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
| Shahneen Sandhu, MBBS, FRACP
|
| Shahneen Sandu presented the preliminary results based on an interim analysis of the PRINCE trial assessing the role of 177-Lu-PSMA-617 in combination with pembrolizumab in men with metastatic castration-resistant prostate cancer (mCRPC). The combination of Lu-PSMA-617 and pembrolizumab has promising activity and manageable toxicity which was consistent with those of single-agent Lu-PSMA-617 and pembrolizumab.
|
|
|
|
|
|
| A Discussion on an Interim Analysis of the Phase Ib PRINCE Study of 177Lu-PSMA-617 in Combination with Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer
|
| Joaquin Mateo, MD, Ph.D.
|
| Following the presentation from Dr. Sandu of the preliminary results of the PRINCE trial of 177Lu-PSMA-617 in Combination with Pembrolizumab for Metastatic Castration-Resistant Prostate Cancer (mCRPC), Joaquin Mateo provided an invited discussion to contextualize these results in the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer genitourinary tumors.
|
|
|
|
|
|
|
|
|
|
|
| Final Overall Survival Analysis from ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide + Androgen Deprivation Therapy in Men with mHSPC
|
| Andrew Armstrong, MD
|
| Andrew Armstrong presented the final overall survival analysis from the ARCHES trial of enzalutamide in men with metastatic hormone-sensitive prostate cancer (mHSPC). Overall survival (OS) represents a key secondary endpoint of the ARCHES trial which was immature at the time of primary analysis and reporting. At this point, there have not been 356 OS events, allowing for final analysis.
|
|
|
|
|
|
| A Discussion on The Final Overall Survival Analysis from ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide + ADT in Men with mHSPC
|
| Stephane M. Oudard, MD, Ph.D.
|
Following the presentation from Dr. Armstrong of the final overall survival analysis of ARCHES examining the role of enzalutamide in metastatic castration sensitive prostate cancer (mCSPC), Stephane Oudard provided an invited discussion to contextualize these results in the Proffered Paper session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer genitourinary tumors.
|
|
|
|
|
|
| Molecular Pathology to Advance Prostate Cancer Precision Medicine
|
| Mark Rubin, MD
|
| Mark Rubin presented the role of molecular pathology to guide treatment for patients with advanced prostate cancer. He began by emphasizing how molecular alternations that occur in the tumorigenesis pathway may influence therapy, and it is particularly important to consider those that may confer treatment resistance.
|
|
|
|
|
|
| Artificial Intelligence To Guide Prostate Cancer Therapeutic Strategies |
| Jean-Emmanuel Bibault, MD, Ph.D. |
| In this presentation, Jean-Emmanuel Bibault discussed the role of artificial intelligence to guide prostate cancer treatment. Artificial intelligence has, thus far, been predominately restricted to a research setting. One of the first applications in prostate cancer has been for the automation of prostate cancer diagnosis and tumor grading on prostate biopsy specimens using neural networks. |
|
|
|
|
|
| Health-Related Quality of Life (HRQoL) in ACIS: a Phase 3 Trial of Apalutamide With Abiraterone Acetate and Prednisone (APA + AAP) vs AAP in Metastatic Castration-Resistant Prostate Cancer (mCRPC),
|
| Stephane M. Oudard, MD, Ph.D.
|
| Stephane Oudard presented data on patient-reported health-related quality of life in the context of the ACIS trial. This phase III trial randomized patients with mCRPC to receive either abiraterone acetate and prednisone with or without apalutamide. In previously presented analyses, the combination regime demonstrated improved radiographic progression-free survival with a 7.4-month improvement in median rPFS.
|
|
|
|
|
|
| Clinical Perspectives for the Individual Patient and the Community
|
| Cora Sternberg MD, FACP
|
| Cora Sternberg presented clinical perspectives for both individual patients and for the community. She began by highlighting that personalized cancer medicine has been popularized in the lay media and wider community through discussion from celebrities of their own personal and family experiences. She concluded in discussing that both NCCN and ESMO guidelines recommend genomic and genetic testing. However, there is huge variability in utilization and access.
|
|
|
|
|
|
|
|
|
|
|
| Systemic Treatments and Novel Approaches
|
| Silke Gillessen, MD
|
| As a portion of the European Society for Medical Oncology (ESMO) Annual Congress, an Educational Session focusing on the management of patients with node-positive locally advanced prostate cancer was held. In this context, Silke Gillessen discussed the role of systemic therapy and novel, emerging treatment approaches.
|
|
|
|
|
|
| TALAPRO-1: Talazoparib Monotherapy in Metastatic Castration-Resistant Prostate Cancer With DNA Damage Response Alterations—Exploration of Non-DDR Mutational Landscape and Potential Associations With Antitumor Activity |
| Niven Mehra, MD, Ph.D. |
| Niven Mehra presented an exploratory ad hoc biomarker analyses assessing non-DDR/HRR mutational landscape and associations with antitumor activity among patients treated with talazoparib for metastatic castration-resistant prostate cancer in the TALAPRO-1 trial. |
|
|
|
|
|
| Safety Analysis of the Phase III IPATential150 Trial of Ipatasertib (Ipat) plus Abiraterone (Abi) in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
|
| Cora Sternberg MD, FACP
|
| Cora Sternberg presented an analysis of the nature and manageability of adverse events of ipatasertib and abiraterone within the context of the IPATential150 trial which compared this combination therapy to abiraterone alone as a first-line treatment approach in metastatic castration-resistant prostate cancer.
|
|
|
|
|
|
| Pain Efficacy With Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer in the PARABO Observational Study |
| Holger Palmedo, Ph.D. |
| Holger Palmedo reported results of the PARABO cohort, a prospective, observational, noninterventional, single-arm study evaluating pain efficacy in patients with metastatic castration-resistant prostate cancer treated with Radium-223 in German real-life nuclear medicine settings. Utilizing these real-world data, patients with mCRPC experienced a reduction of bone-associated pain during Radium-223 therapy, regardless of EOD or opioid use. The benefit appeared most pronounced in patients who received 5–6 cycles of Radium-223. |
|
|
|
|
|
| Analysis of Serial PET Imaging and Paired Tc99 Scans in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide
|
| Ravi Madan, MD
|
| Ravi Madan provided an assessment of a semi-automated method of assessing Sodium Fluoride (NaF) PET using a novel technology. This is particularly relevant given that current and emerging PET platforms are enhancing clinicians’ ability to evaluate metastatic lesions in mCRPC. Based on the data, serial NaF PET-CT can illustrate dynamic changes in patients with mCRPC treated with enzalutamide. Further, interval development of lesions visible on NaF PET may not predict rPD seen on Tc99.
|
|
|
|
|
|
| Patient-Reported Outcomes in Prostate Cancer Patients Receiving PSMA-Targeted Radionuclide Therapy |
| Brian Gonzalez, Ph.D. |
| Brian Gonzalez presents an assessment of patient-reported outcomes in prospective clinical trials, using linear mixed model analyses with no imputation for missing data among participants with evaluable data to examine whether PROs changed over time and whether a change in PROs was associated with treatment received, baseline clinical factors, and response to treatment. |
|
|
|
|
|
|
|
| To view our full coverage of the 2021 ESMO Annual Congress, visit the Conference Coverage section on UroToday.com |
|
|
|
|
|
 |
|
|
|
|
